CLLS News

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

Cellectis Reports Financial Results for the First Quarter 2026

Cellectis to Report First Quarter Financial Results on May 11, 2026

Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026